CDR-Life Inc., a biotherapeutics company developing tumor-specific immunotherapies based on a proprietary antibody platform, today announced the expansion of its leadership team with the appointment of Björn Peters as chief business officer.
Boehringer Ingelheim has signed a collaboration and licensing agreement with CDR-Life for the research and development of antibody fragment-based therapeutics to treat geographic atrophy (GA).